News
BMS lines up follow-up indication for cardiomyopathy drug Ca...
Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the compan
